CSI Singapore and Next&Bio Launch Joint Organoid Research Laboratory at NUS
We are excited to announce the launch of a joint organoid research laboratory by Next&Bio and the Cancer Science Institute of Singapore (CSI Singapore), hosted at the National University of Singapore (NUS).
This strategic collaboration aims to:
- 🔬 Build Asia’s largest organoid biobank from Asian cancer patients
- 🌏 Advance precision oncology with better population representation
- 💊 Develop innovative, animal-free preclinical drug testing platforms
Official Signing Ceremony
The agreement was formally signed on 30 July 2025 in Singapore. Key attendees included:
- Professor Ashok Venkitaraman, Director, CSI Singapore
- Dr. Sang-wook Park, CEO, Next&Bio
- Mr. Jason Cho, Director, Next&Bio
- Representatives from K-Startup Center Singapore
A Word from Professor Ashok Venkitaraman
“We are delighted to join forces with Next&Bio in this collaboration. Cancer organoids have emerged as important tools in the fight against cancer, but few currently represent the genetic diversity of cancers that occur amongst Singaporeans.
The reproducible and robust creation of organoids requires a high level of expertise, which Next&Bio has already developed. So my colleagues and I believe that this research collaboration will help us to better understand Asian cancers to develop new treatments that benefit Singapore’s cancer patients.”
This partnership marks a significant step forward in inclusive and globally impactful translational cancer research — with the potential to shape the future of personalised medicine and ethical, patient-representative drug development.
